Overview

HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol

Status:
Completed
Trial end date:
1996-04-01
Target enrollment:
Participant gender:
Summary
To evaluate short-term and long-term safety and efficacy of intravenous cidofovir (HPMPC) for treatment of small peripheral cytomegalovirus (CMV) retinitis lesions. To provide data on the relative safety and efficacy of 2 doses of HPMPC as maintenance regimens.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Gilead Sciences
Treatments:
Cidofovir
Probenecid